Last reviewed · How we verify
KH902
At a glance
| Generic name | KH902 |
|---|---|
| Sponsor | Chengdu Kanghong Biotech Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection (NA)
- Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy (PHASE4)
- Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy (NA)
- Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema (NA)
- Evaluation of RC28-E Injection in Diabetic Macular Edema (PHASE2)
- A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD (PHASE3)
- Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients (PHASE2)
- Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KH902 CI brief — competitive landscape report
- KH902 updates RSS · CI watch RSS
- Chengdu Kanghong Biotech Co., Ltd. portfolio CI